A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo

NCT01005901 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1324

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: Glycopyrronium bromide
DRUG: Placebo

Sponsor

Novartis